Onapristone

奥纳司酮

Report date: 2022/09/22 14:07:58
NME

Base Information

Drug NameOnapristone
Drug Alias Name欧纳氏酮OnapristonumOnapristone extended-release奥那司酮Onapristona +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProgesterone receptor antagonists
TargetsProgesterone receptor
Therapy Area/IndicationsMetastatic breast cancerNeoplasm MetastasisProstatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBayer Schering Pharma GmbhContext Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesContext Therapeutics IncMenarini GroupThomas Jefferson University +[4] 
Inactive CompaniesUniversity Of Wisconsin-MadisonArno Therapeutics Inc
Active IndicationsEndometrial NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[4] 
Inactive IndicationsMetastatic breast cancerNeoplasm MetastasisProstatic Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksKEGG